The BBC speaks with 23andMe's Linda Avey and Anne Wojcicki about their company and their motivation. "The reason we started this company is that we really dramatically wanted to change healthcare," Wojcicki tells the BBC. Avey adds that they think that if people know their genetic information, they will take better care of themselves. The BBC also mentions that FDA is "warming to personal gene services," though the public still has some concerns.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.